Home » Stocks » Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (APLS)

Stock Price: $32.96 USD 1.00 (3.13%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.49B
Revenue (ttm) n/a
Net Income (ttm) -422.95M
Shares Out 75.50M
EPS (ttm) -6.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $32.96
Previous Close $31.96
Change ($) 1.00
Change (%) 3.13%
Day's Open 32.31
Day's Range 31.85 - 33.21
Day's Volume 663,499
52-Week Range 16.85 - 45.04

More Stats

Market Cap 2.49B
Enterprise Value 2.00B
Earnings Date (est) Jul 29, 2020
Ex-Dividend Date n/a
Shares Outstanding 75.50M
Float 54.96M
EPS (basic) -6.62
EPS (diluted) -6.39
FCF / Share -3.87
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.75M
Short Ratio 10.47
Short % of Float 17.77%
Beta 1.27
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 9.25
Revenue n/a
Operating Income -338.06M
Net Income -422.95M
Free Cash Flow -285.18M
Net Cash 489.02M
Net Cash / Share 6.48
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -41.96%
ROE -174.86%
ROIC -253.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 9
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(63.83% upside)
Current: 32.96
Target: 54.00
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-288-128-50.91-27.26-46.57
Net Income-305-128-51.01-27.12-46.52
Shares Outstanding62.2354.4013.878.435.80
Earnings Per Share-4.90-2.34-3.68-3.22-8.03
Operating Cash Flow-211-131-46.60-26.00-18.86
Capital Expenditures-1.69----
Free Cash Flow-213-131-46.60-26.00-18.86
Cash & Equivalents35217617624.8636.00
Total Debt15727.0426.39--
Net Cash / Debt19514914924.8636.00
Book Value34.2316114923.7934.98
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Apellis Pharmaceuticals, Inc.
Country United States
Employees 266
CEO Cedric Francois

Stock Information

Ticker Symbol APLS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APLS
IPO Date November 9, 2017


Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for intravenous administration in systemic indications. It has a risk-sharing collaboration agreement with SFJ Pharmaceuticals Group for the development of APL-2 in hematologic indications. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.